Risk of Dementia in Patients with Depression or Parkinson’s Disease: A Retrospective Cohort Study

Fang, Ting-Chun; Wu, Yu‐Hsuan; Chen, Yi-Huei; Lin, Ching‐Heng; Chang, Ming-Hong

doi:10.1155/2020/8493916

Cited by 10 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD, which occurs especially in the elderly, is a chronic disorder involving neurodegenerative changes that lead to the deprivation of dopaminergic neurons in the substantia nigra and a subsequent reduction of dopamine level in the striatum, resulting in tremor, myotonia and dyskinesia (Shen et al ., 2021). In the clinical, PD is often associated with multiple complications such as sleep disorders, depression and LUTS (Airavaara et al ., 2020; Fang et al ., 2020; Martinez-Ramirez et al ., 2020). These morbid complications usually indicated an increased likelihood of hospitalization, polypharmacy, adverse drug effects including the anticholinergic burden of medications, drug–disease and drug–drug interactions (Tenison and Henderson, 2020).…”

Section: Discussionmentioning

confidence: 99%

“…AD, Alzheimer's disease; LUTS, lower urinary tract symptoms; PD, Parkinson's disease. Fang et al, 2020;Martinez-Ramirez et al, 2020). These morbid complications usually indicated an increased likelihood of hospitalization, polypharmacy, adverse drug effects including the anticholinergic burden of medications, drug-disease and drug-drug interactions (Tenison and Henderson, 2020).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends of complications in patients with Parkinson’s disease in seven major cities of China from 2016 to 2019

Chen²,

Zhu³

et al. 2021

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurological disorder involving both motor and nonmotor symptoms. Multimorbidity acts synergistically to heighten the risk of adverse outcomes for patients with PD. Its complications have a major impact on the clinical management of PD. The present retrospective and multicenter study was first performed to describe the epidemiological characteristics of PD patients and assess the incidence of complications. The outpatient prescriptions for PD therapy were collected from hospitals in Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin and Zhengzhou of China over a 40-day period per year, from the first half of 2016 to that of 2019. The survey covered the characteristics and representative complications of the study population. A total of 103 674 outpatient prescriptions for PD treatment from different graded hospitals of China were collected for final data analysis. It showed that 78.15% of PD patients were prescribed in the neurology department. 95.05% of the outpatient prescriptions were from general hospitals. We found that the overall PD prevalence was 0.47%, among which 52.96% of them were men. In addition, 82.10% of PD suffers were older than 60 years and 83.70% of them had complications. The top five highest frequencies of nonmotor complications in PD patients were sleep disorders, Alzheimer’s disease, depression, lower urinary tract symptoms and constipation, with the proportions of 6.79, 3.87, 3.72, 3.32 and 2.40%, respectively. Meanwhile, the proportions of sleep disorders, Alzheimer’s disease, and constipation were gradually increasing from 2016 to 2019. The characteristics of PD patients and the incidence of its complications were evaluated in the present prescription survey. These updated data provide evidence for further implementation of PD management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Trends of complications in patients with Parkinson’s disease in seven major cities of China from 2016 to 2019

Chen²,

Zhu³

et al. 2021

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…To increase our diagnostic validity, the subjects were included only when the diagnosis was made in three or more consecutive outpatient visits or in one or more inpatient settings during follow-up in 1996-2011. Similar to our previous researches (22,23), we excluded patients encoded with the diseases possibly causing secondary parkinsonism (for example: stroke, hydrocephalus, hypoxic encephalopathy. .…”

Section: Study Design and Populationmentioning

confidence: 99%

Age-Stratified Risk of Dementia in Parkinson's Disease: A Nationwide, Population-Based, Retrospective Cohort Study in Taiwan

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Parkinson's disease (PD) manifests with dominant motor symptoms and a wide range of non-motor symptoms (NMS). Dementia is one of the most disabling and exhausting NMS throughout the clinical course. We conducted a population-based, age-stratified, retrospective cohort study to investigate the incidence rate and risk of dementia of patients with newly diagnosed PD, and linked to the clinicopathological PD subtypes.Methods: Patients with newly diagnosed PD (PD group, n = 760) and control subjects (non-PD group, n = 3,034) were selected from the Taiwan's National Health Insurance Research Database from January 2001 to December 2005. The dementia incidence rate and dementia-free survival rate were calculated.Results: The overall dementia incidence rate was 17.5 and 5.7 per 1,000 person-years in PD and non-PD groups, respectively. The PD group had a significantly higher overall risk of dementia than controls (p < 0.001). The younger PD patients had a lower dementia incidence rate than the older PD patients, but a higher dementia risk compared to the same age of controls (<60 years, adjusted HR 6.55, 95% CI 1.56–27.48, p = 0.010). The dementia-free survival rate was significantly lower in the PD group compared to the non-PD group during follow-up (p < 0.001).Conclusion: In our study, the older age of onset in PD patients resulted in a higher incidence rate of dementia. In the young age of PD patients, the incidence rate of dementia was lower than the older PD patients, but the dementia risk was higher than controls of the same age. These findings possibly implied that there were different pathogenesis and pathologies causing dementia in younger and older PD patients.

show abstract

Old dog, new tricks: Polydatin as a multitarget agent for current diseases

Jiang

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

Polydatin (PD) is a natural single‐crystal product that is primarily extracted from the traditional plant Polygonum cuspidatum Sieb. et Zucc. Early research showed that PD exhibited a variety of biological activities. PD has attracted increasing research interest since 2014, but no review comprehensively summarized the new findings. A great gap between its biological activities and drug development remains. It is necessary to summarize new findings on the pharmacological effects of PD on current diseases. We propose that PD will most likely be used in cardiac and cerebral ischaemia/reperfusion‐related diseases and atherosclerosis in the future. The present work classified these new findings according to diseases and summarized the main effects of PD via specific mechanisms of action. In summary, we found that PD played a therapeutic role in a variety of diseases, primarily via five mechanisms: antioxidative effects, antiinflammatory effects, regulation of autophagy and apoptosis, maintenance of mitochondrial function, and lipid regulation.

show abstract

Risk of Dementia in Patients with Depression or Parkinson’s Disease: A Retrospective Cohort Study

Cited by 10 publications

References 22 publications

Trends of complications in patients with Parkinson’s disease in seven major cities of China from 2016 to 2019

Trends of complications in patients with Parkinson’s disease in seven major cities of China from 2016 to 2019

Age-Stratified Risk of Dementia in Parkinson's Disease: A Nationwide, Population-Based, Retrospective Cohort Study in Taiwan

Old dog, new tricks: Polydatin as a multitarget agent for current diseases

Contact Info

Product

Resources

About